Matches 1 - 36 out of 36
Match Document Document Title
7351855 Chemically defined non-polymeric valency platform molecules and conjugates thereof  
Chemically-defined, non-polymeric valency platform molecules and conjugates comprising chemically-defined valency platform molecules and biological or chemical molecules including polynucleotide...
EP1808183A2 Chemically-defined non-polymeric valency platform molecules and conjugates thereof  
Chemically-defined, non-polymeric valency platform molecules and conjugates comprising chemically-defined valency platform molecules and biological or chemical molecules including polynucleotide...
7208156 Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform molecule  
Conjugates of nonimmunogenic valency platform molecules and analogs of immunogens that possess the specific B cell binding ability of the immunogen but lack T cell epitopes and which, when...
7163683 Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform molecule  
Conjugates of nonimmunogenic valency platform molecules and analogs of immunogens that possess the specific B cell binding ability of the immunogen but lack T cell epitopes and which, when...
7138244 Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform molecule  
Conjugates of nonimmunogenic valency platform molecules and analogs of immunogens that possess the specific B cell binding ability of the immunogen but lack T cell epitopes and which, when...
7115581 Chemically-defined non-polymeric valency platform molecules and conjugates thereof  
Chemically-defined, non-polymeric valency platform molecules and conjugates comprising chemically-defined valency platform molecules and biological or chemical molecules including polynucleotide...
7084256 Self antigen vaccines for treating B cell lymphomas and other cancers  
A polypeptide self-antigen useful in a tumor-specific vaccine mimics one or more epitopes of an antigen uniquely expressed by cells of the tumor. The polypeptide is preferably produced in a plant...
7083959 Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry  
The present invention relates to a method of specifically suppressing an undesired immune response in a mammal suffering from such a response. The method comprises: i) preparing a construct...
6951939 Multivalent platform molecules comprising high molecular weight polyethylene oxide  
Valency platform molecules comprising high molecular weight polyethylene oxide groups are provided, as well as conjugates thereof with biologically active molecules, and methods for their...
6858210 Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same  
The present invention provides domain 1 β 2 GPI polypeptides, polynucleotides encoding these polypeptides, mimetics of these polypeptides, and methods using domain 1 β 2 GPI polypeptides and...
6458953 Valency platform molecules comprising carbamate linkages  
This invention pertains generally to valency molecules, such as valency platform molecules which act as scaffolds to which one or more molecules may be covalently tethered to form a conjugate. More...
6399578 Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same  
This invention provides conjugates useful for xenotransplantation which comprise a galactose α1,3 galactosyl (αGal) epitope conjugated to a valency platform molecule, preferably a chemically...
6340460 Therapeutic suppression of specific immune response by administration of oligomeric forms of antigen of controlled chemistry  
A method of making a non-immunogenic construct for reducing a non-primary antibody response to an epitope of a T-dependent antigen by coupling two or more copies of the epitope to a nonimmunogenic...
6207160 aPL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibody-mediated pathologies  
aPL analogs that (a) bind specifically to B cells to which an aPL epitope binds and are disclosed. Optimized analogs lack T cell epitope(s) are useful as conjugates for treating aPL...
6060056 Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform molecule  
Conjugates of nonimmunogenic valency platform molecules and analogs of immunogens that possess the specific B cell binding ability of the immunogen but lack T cell epitopes and which, when...
5874552 Modified phosphorous intermediates for providing functional groups on the 5' end of oligonucleotides  
Phosphoramidites of the formula ##STR1## where R is a base-labile protecting group, R 1 and R 2 are individually alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, or aryl of 6 to...
5786512 Modified phosphorous intermediates for providing functional groups on the 5' end of oligonucleotides  
Phosphoramidites of the formula ##STR1## where R is a base-labile protecting group, R 1 and R 2 are individually alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, or aryl of 6 to...
5726329 Modified phosphorous intermediates for providing functional groups on the 5' end of oligonucleotides  
Phosphoramidites of the formula ##STR1## where R is a base-labile protecting group, R 1 and R 2 are individually alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, or aryl of 6 to...
5633395 Chemically-defined non-polymeric valency platform molecules and conjugates thereof  
Chemically-defined, non-polymeric valency platform molecules and conjugates comprising chemically-defined valency platform molecules and biological or chemical molecules including polynucleotide...
5606047 Chemically-defined non-polymeric valency platform molecules and conjugates thereof  
Chemically-defined, non-polymeric valency platform molecules and conjugates comprising chemically-defined valency platform molecules and biological or chemical molecules including polynucleotide...
5552391 Chemically-defined non-polymeric valency platform molecules and conjugates thereof  
Chemically-defined, non-polymeric valency platform molecules and conjugates comprising chemically-defined valency platform molecules and biological or chemical molecules including polynucleotide...
EP0438259B1 Conjugates of biologically stable polymers and polynucleotides for treating systemic lupus erythematosus  
Abstract of EP0438259 Chemically defined conjugates of biologically stable polymers, such as copolymers of D-glutamic acid and D-lysine, and polynucleotide duplexes of at least 20 base pairs that...
5391785 Intermediates for providing functional groups on the 5' end of oligonucleotides  
Phosphoramidites of the formula ##STR1## where R is a base-labile protecting group, R 1 and R 2 are individually alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, or aryl of 6 to...
5370871 Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry  
The present invention relates to a vaccine derived from a bacterial or virus product that initially comprises a mixture of polymers of varying molecular weights. The vaccine contains an...
5276013 Conjugates of biologically stable polyfunctional molecules and polynucleotides for treating systemic lupus erythematosus  
Chemically defined conjugates of biologically stable valency platform molecules, such as copolymers of D-glutamic acid and D-lysine or polyethylene glycol, and polynucleotide duplexes of at least...
EP0272278B1 $i(D)-GL CONJUGATE THERAPY  
Abstract not available for EP0272278 Abstract of corresponding document: WO8707145 Receptor blocking technology using proteins conjugated to polymers of D-glutamic acid and D-lysine for treatment...
5162515 Conjugates of biologically stable polymers and polynucleotides for treating systemic lupus erythematosus  
Chemically defined conjugates of biologically stable polymers, such as copolymers of D-glutamic acid and D-lysine, and polynucleotide duplexes of at least 30 base pairs that have significant...
5126131 Therapeutic suppression of specific immune responses by administration of antigen-competitive conjugates.  
Undesired immune responses are suppressed by administering a nonimmunogenic material which comprises one or more haptens or epitopes corresponding to the antigen which causes the undesired immune...
EP0438259A1 Conjugates of biologically stable polymers and polynucleotides for treating systemic lupus erythematosus.  
Chemically defined conjugates of biologically stable polymers, such as copolymers of D-glutamic acid and D-lysine, and polynucleotide duplexes of at least 20 base pairs that have significant...
5017648 D-GL conjugate therapy  
Receptor blocking technology using proteins conjugated to polymers of D-glutamic acid and D-lysine for treatment of antibody-mediated autoimmune disease, membrane and tumor disorders is disclosed.
4950713 Conjugates of D-glutamic acid: D-lysine copolymer and certain biochemicals  
Receptor blocking technology using proteins conjugated to polymers of D-glutamic acid and D-lysine for treatment of antibody-mediated autoimmune disease, membrane and tumor disorders is disclosed.
4950469 D-GL conjugate therapy  
Receptor blocking technology using proteins conjugated to polymers of D-glutamic acid and D-lysine for treatment of antibody-mediated autoimmune disease, membrane and tumor disorders is disclosed.
EP0077158A1 Modified allergens.  
A process for preparing a polysarcosine modified allergen comprises binding polysarcosine in the form of a compound of formula (I): wherein R is a C1-6 alkyl group, preferably methyl, n is 1 or...
4276206 Immunochemical conjugates: method and composition  
Techniques for preparing stable conjugates of protein-D-GL which can then be isolated in pure form are disclosed, using hen egg ovalbumin (OVA) as a prototype protein, and conjugation and...
4253996 Immunochemical conjugates: method and composition  
Techniques for preparing stable conjugates of protein-D-GL which can then be isolated in pure form are disclosed, using hen egg ovalbumin (OVA) as a prototype protein, and conjugation and...
4253995 Immunochemical conjugates: method and composition  
Techniques for preparing stable conjugates of protein-D-GL which can then be isolated in pure form are disclosed, using hen egg ovalbumin (OVA) as a prototype protein, and conjugation and...
Matches 1 - 36 out of 36